Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II: Implications for ribavirin metabolism in erythrocytes

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2164-2171

  Wu, Jim Zhen ^a   Larson, Gary ^a   Walker, Heli ^a   Shim, Jae Hoon ^a   Hong, Zhi ^a  

^a Drug Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; 5' NUCLEOTIDASE; ADENOSINE; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE KINASE; INOSINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; PHOSPHATE; RIBAMIDINE; RIBAVIRIN; SODIUM CHLORIDE; URIDINE KINASE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ERYTHROCYTE; HEMOLYTIC ANEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE;

5'-NUCLEOTIDASE; ADENOSINE KINASE; ANIMALS; ANTIVIRAL AGENTS; CRICETINAE; CYTOSOL; ERYTHROCYTES; HUMANS; KINETICS; PHOSPHORYLATION; RIBAVIRIN;

EID: 19544363065     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2164-2171.2005     Document Type: Article

References (39)

1. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23.
2. Banditelli, S., C. Baiocchi, R. Pesi, S. Allegrini, M. Turriani, P. L. Ipata, M. Camici, and M. G. Tozzi. 1996. The phosphotransferase activity of cytosolic 5′-nucleotidase; a purine analog phosphorylating enzyme. Int. J. Biochem. Cell. Biol. 28:711-720.
3. Bennett, L. L., Jr., P. W. Allan, G. Arnett, Y. F. Shealy, D. S. Shewach, W. S. Mason, I. Fourel, and W. B. Parker. 1998. Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2′-deoxyguanosine: substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5′-nucleotidase. Antimicrob. Agents Chemother. 42:1045-1051.
4. Blanchi, V., and J. Spychala. 2003. Mammalian 5′-nucleotidases. J. Biol. Chem. 278:46195-46198.
5. Bontemps, F., M. F. Vincent, F. Van den Bergh, G. van Waeg, and G. Van den Berghe. 1989. Stimulation by glycerate 2,3-bisphosphate: a common property of cytosolic IMP-GMP 5′-nucleotidase in rat and human tissues. Biochim. Biophys. Acta 997:131-134.
6. Bougie, I., and M. Bisaillon. 2004. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J. Biol. Chem. 279:22124-22130.
7. Carreras, J., R. Bartrons, F. Climent, and R. Cusso. 1986. Bisphosphorylated metabolites of glycerate, glucose, and fructose: functions, metabolism and molecular pathology. Clin. Biochem. 19:348-358.
8. Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
9. De Franceschi, L., G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, F. Manzato, F. Noventa, A. M. Stanzial, P. Solero, and R. Corrocher. 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:997-1004.
10. Fridland, A., M. C. Connelly, and T. J. Robbins. 1986. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5′-nucleotidase. Cancer Res. 46:532-537.
11. Fried, M. W. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:8237-8244.
12. Goswami, B. B., E. Borek, O. K. Sharma, J. Fujitaki, and R. A. Smith. 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89:830-836.
13. Harki, D. A., J. D. Graci, V. S. Korneeva, S. K. Ghosh, Z. Hong, C. E. Cameron, and B. R. Peterson. 2002. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D- ribofuranosyl-3-nitropyrrole. Biochemistry 41:9026-9033.
14. Homma, M., Y. Matsuzaki, Y. Inoue, M. Shibata, K. Mitamura, N. Tanaka, and Y. Kohda. 2004. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin. Gastroenterol. Hepatol. 2:337-339.
15. Hong, Z., E. Ferrari, A. Skelton, J. Wright-Minogue, W. Zhong, and C. A. Lesburg. 2002. Effects of genotype variations on hepatitis C nonstructural protein 5B structure and activity, p. 109-121. In R. F. Schinazi, C. M. Rice, and J. P. Sommadossi (ed.), Therapies for viral hepatitis. Elsevier Science, Amsterdam, The Netherlands.
16. Hui, D. S., and G. W. Wong. 2004. Advancements in the battle against severe acute respiratory syndrome. Expert Opin. Pharmacother. 5:1687-1693.
17. Jarvis, S. M., J. A. Thorn, and P. Glue. 1998. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br. J. Pharmacol. 123:1587-1592.
18. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
19. Lin, C. C., D. Lourenco, G. Xu, and L. T. Yeh. 2004. Disposition and metabolic profiles of [14-C]viramidine and [14-C]ribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother. 48:1872-1875.
20. Lin, C. C., L.- T. Yeh, D. Vitarella, and Z. Hong. 2003. Viramidine, a liver-targeting ribavirin prodrug, show better liver-targeting properties and safety profile than ribavirin in animals. Antiviral Chem. Chemother. 14:145-152.
21. Maj, M. C., B. Singh, and R. S. Gupta. 2000. Structure-activity studies on mammalian adenosine kinase. Biochem. Biophys. Res. Commun. 275:386-393.
22. Noble, S. A., N. E. Beddall, A. J. Beveridge, C. L. Marr, C. L. Mo, P. L. Myers, C. R. Penn, R. Storer, and J. M. Woods. 1991. Synthesis and biological evaluation of carbocyclic analogues of ribavirin. Nucleosides Nucleotides 10:487-490.
23. Oka, J., A. Matsumoto, Y. Hosokawa, and S. Inoue. 1994. Molecular cloning of human cytosolic purine 5′-nucleotidase. Biochem. Biophys. Res. Commun. 205:917-922.
24. Page, T., and J. D. Connor. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22:379-383.
25. Pesi, R., M. Turriani, S. Allegrini, C. Scolozzi, M. Camici, P. L. Ipata, and M. G. Tozzi. 1994. The bifunctional cytosolic 5′-nucleotidase: regulation of the phosphotransferase and nucleotidase activities. Arch. Biochem. Biophys. 312:75-80.
26. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
27. Saunders, P. P., C. D. Spindler, M. T. Tan, E. Alvarez, and R. K. Robins. 1990. Tiazofurin is phosphorylated by three enzymes from Chinese hamster ovary cells. Cancer Res. 50:5269-5274.
28. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
29. Spychala, J., V. Chen, J. Oka, and B. S. Mitchell. 1999. ATP and phosphate reciprocally affect subunit association of human recombinant high Km 5′-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. Eur. J. Biochem. 259:851-858.
30. Spychala, J., N. S. Datta, K. Takabayashi, M. Datta, I. H. Fox, T. Gribbin, and B. S. Mitchell. 1996. Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc. Natl. Acad. Sci. USA 93:1232-1237.
31. Streeter, D. G., J. P. Miller, R. K. Robins, and L. N. Simon. 1977. The enzymic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5′- phosphate and its relationship to the proposed mechanism of action. Ann. N. Y. Acad. Sci. 284:201-210.
32. Streeter, D. G., L. N. Simon, R. K. Robins, and J. P. Miller. 1974. The phosphorylation of ribavirin by deoxyadenosine kinase from rat liver. Differentiation between adenosine and deoxyadenosine kinase. Biochemistry 13:4543-4549.
33. Streeter, D. G., J. T. Witkowski, G. P. Khare, R. W. Sidwell, R. J. Bauer, R. K. Robins, and L. N. Simon. 1973. Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70:1174-1178.
34. Tam, R. C., B. Pai, J. Bard, C. Lim, D. R. Averett, U. T. Phan, and T. Milovanovic. 1999. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30:376-382.
35. Willis, R. C., D. A. Carson, and J. E. Seegmiller. 1978. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc. Natl. Acad. Sci. USA 75:3042-3044.
36. Wray, S. K., B. E. Gilbert, and V. Knight. 1985. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5:39-48.
37. Wu, J. Z., G. Larson, and Z. Hong. 2004. Dual-aclion mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob. Agents Chemother. 48:4006-4008.
38. Wu, J. Z., C. C. Lin, and Z. Hong. 2003. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J. Antimicrob. Chemother. 52:543-546.
39. Wu, J. Z., H. Walker, J. Y. Lau, and Z. Hong. 2003. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 47:426-431.